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eFIMMG (Italian Federation of General Practitioner) Verona Study Center, ItalyAbstractObjectives: Familial hypercholesterolemia (FH) is the most common monogenic lipid disorder associated with premature coronary heart
disease. Early cholesterol-lowering therapy could effectively reduce cardiovascular disease morbidity and mortality in these patients.
However, the majority of people with FH are undiagnosed, also due to low awareness and knowledge of FH in general practice, despite the
high number of contacts GPs have with most of their patients which allows a systematic and effective approach to the detection of this
condition. Here, we present a simple method to improve detection and to enhance awareness of FH in primary care using GP electronic
health records.
Methods: We used electronic data from the Co.S. Consortium, involving more than 600 Italian affiliated GPs. Electronic data include
demographic information, laboratory test results, recorded history of vascular disease and prescription of an HMG-CoA reductase inhibitor
class medication. We performed a partial assessment of the Dutch Lipid Clinic Network (DLCN) score using those data that were recorded
or available. We also sought to determine the prevalence of possible FH based on age-specific LDL-cholesterol thresholds employed by the
diagnostic criteria of MEDPED and the non-age adjusted cut-off point (LDL-C 190 mg/dL).
Results: Data on LDL-C were available for 162,864 subjects. Mean LDL-C levels (SD) were 124.3 (33.6) mg/dL for non-treated subjects
and 106.4 (38.5) mg/dL for statin-treated subjects. The cut-off of LDL-C 190 mg/dL yielded a prevalence of 2.9% among non-treated
subjects and of 3.5% among statin-treated patients. Using the cut-off of 250 mg/dL, the prevalence was 0.1% among non-treated
subjects and 0.3% among statin-treated patients. Using the cut-off 330 mg/dL (suggesting a probable diagnosis of FH according to
the DLCN score) the prevalence was 0.01% and 0.02%. According to the stratification proposed by MEDPED criteria for the general
population, the age-specific LDL-cholesterol thresholds identified 0.7% among non-treated subjects and 18.5% among statin-treated
patients.
Conclusion: The diagnosis of FH is possible in general medicine and should be an integral part of the GP’s activity.
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creativecommons.org/licenses/by-nc-nd/4.0/).
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26 M. Casula et al. / Atherosclerosis Supplements 29 (2017) 25e301. Introduction prescription of an HMG-CoA reductase inhibitor classPlasma cholesterol levels are controlled by genetic and
environmental factors. Primary or familial dyslipidemias
are inherited diseases caused by a single genetic mutation
in one of several genes. Genetic abnormalities that lead to
abnormal blood lipid levels are mainly found in genes
involved in the transportation and cellular uptake of lipids.
Individuals who have these mutations often have severely
abnormal blood lipid levels, which results in early-onset
cardiovascular disease [1].
One of the most frequent forms is familial hypercho-
lesterolemia (FH), an inherited disease in which genetic
alteration results in the increase of low-density lipoprotein
cholesterol (LDL-C) levels [2]. The frequency of hetero-
zygous FH is estimated at about 1:200e1:250 in the
general population [3e6], resulting in one of the most
common monogenic disorders. The homozygous form
(HoFH) is very rare, with an estimated rate of 1:1,000,000
people [7]. Individuals with heterozygous FH (HeFH) have
total cholesterol and LDL-C plasma levels between 300
and 500 mg/dL (7.75e13 mmol/L). In HoFH, these levels
are significantly higher (600e1200 mg/dL;
15.5e31.0 mmol/L).
Early diagnosis of FH is crucial because the disease
should be early treated with lipid-lowering therapy and
lifestyle changes to prevent cardiovascular complications
[8,9]. In Italy, it has been estimated that <1% of cases are
actually recognized and there is a general lack of uniform
public health initiatives specifically directed to close the
gap of knowledge on FH [5].
The frequency and clinical significance of these condi-
tions justify a major effort to identify affected individuals
and their families, a task entrusted almost entirely to
general practitioners (GPs). In fact, the high number of
contacts by GPs with most of patients allows a systematic
and effective approach to the detection of this condition
[10]. In a context where systematic screening is not applied,
in addition to cascade screening after the identification of
an index patient, opportunistic screening through the
routinely clinical practice is the only opportunity to identify
FH patients. Here, we present a simple method to improve
detection and to enhance awareness of FH in primary care
using GP electronic health records (GP EHR).2. Methods
We used electronic data from the Consorzio Sanita` e
Co.S. (see Appendix). Data were collected by more than
600 Italian GPs affiliated with the Consortium, who in their
daily clinical practice periodically extracted data which,
after anonymization, were collected in the “My Search”
database.
Electronic data include demographic information, labo-
ratory test results, recorded history of vascular disease and(statin) medication.
We performed a partial assessment of the Dutch Lipid
Clinic Network (DLCN) score using those data that were
recorded or available. The DLCN score includes assess-
ment of: raised cholesterol and LDL-C concentrations,
clinical characteristics (such as peripheral vascular disease;
coronary artery disease), presence of tendon xanthoma or
arcus cornealis, and a family history of premature heart
disease [11]. The data extracted did not contain family
history or examination findings, therefore the partial DLCN
score assessment only included LDL-C concentrations and,
where recorded, a personal history of vascular disease. The
score determines the likelihood of an FH diagnosis as
unlikely (<3 points), possible (3e5 points), probable (6e8
points), or definite (>8 points) FH.
We also sought to determine the prevalence of possible
FH based on age-specific LDL-cholesterol thresholds
employed by the diagnostic criteria of MEDPED [12] and
the non-age adjusted cut-off point (LDL-C 190 mg/dL)
adopted by the Italian Medicines Agency (AIFA) to regu-
late reimbursement of lipid lowering drugs in Italy, together
with personal or familial history of premature coronary
artery disease or tendinous xanthomata.
Descriptive statistics were calculated to describe patient
characteristics. All analysis and results were completed in
IBM SPSS Statistics version 23.3. Results
Data on LDL-C were available for 162,864 subjects.
Among them, 22.9% were on statin treatment. Mean LDL-
C levels (SD) were 124.3 (33.6) mg/dL for non-treated
subjects and 106.4 (38.5) mg/dL for statin-treated
subjects. The serum LDL-C distribution for non-treated
and statin-treated subjects is shown in Fig. 1A and B,
respectively. The median serum LDL-C concentrations
were 123.4 mg/dL. The 95th and 99th percentiles for serum
LDL-C were 180.4 and 207.8 mg/dL, respectively.
The cut-off adopted by the Italian Medicines Agency of
LDL-C 190 mg/dL yielded a prevalence of 2.9% among
non-treated subjects and of 3.5% among statin-treated
patients. Importantly, this last value is likely to be under-
estimated, as calculated on LDL-C levels reduced due to
the lipid-lowering therapy. Assuming an average 30%
reduction in LDL-C achieved by statin therapy and back-
calculating hypothetical pre-treatment levels, the applica-
tion of this cut-off would identify 20.8% of treated subjects
(7.0% of the total sample).
If we considered the most recently estimated prevalence
of FH in the general population of 1:200e1:250 [13], the
cut-off of LDL-C in this population of untreated subjects
would be 218 and 222 mg/dL, respectively.
The cut-off of 190 mg/dL also corresponds to the lowest
threshold for the stratification of the levels of LDL-C
Fig. 1. A. Plasma LDL-cholesterol distribution of non-treated subjects (N ¼ 125,609). B. Plasma LDL-cholesterol distribution of statin-treated subjects
(N ¼ 37,254).
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3 points for the clinical diagnosis of FH.
Using the next cut-off (250 mg/dL), which gives 5
points according to the DLCN score, the prevalence was
0.1% among non-treated subjects and 0.3% among statin-
treated patients. Using the cut-off 330 mg/dL, whichgives 8 points according to the DLCN score, i.e. a probable
diagnosis of FH, the prevalence was 0.01% and 0.02%,
respectively. According to the stratification proposed by
MEDPED criteria for the general population, the age-
specific LDL-cholesterol thresholds identified 0.7%
among non-treated subjects and of 18.5% among statin-
Table 1
Potential FH prevalence based on DLCN score.
Non-treated subjects Statin-treated patients
Number of people
meeting the criteria
Prevalence Number of people
meeting the criteria
Prevalence
190 mg/dL (possible FH) 3651 1:34 1291 1:29
250 mg/dL (probable FH) 121 1:1038 101 1:369
330 mg/dL (probable FH) 7 1:17,944 8 1:4657
Table 2
Potential FH prevalence based on MEDPED criteria.
Number of people meeting
the criteria
Non-treated
subjects
Statin-treated
patients
Age <20 years, LDL-cholesterol
200 mg/dL
3 0
Age 20e29 years, LDL-cholesterol
220 mg/dL
7 2
Age 30e39 years, LDL-cholesterol
240 mg/dL
17 6
Age 40 years, LDL-cholesterol
260 mg/dL
64 61
Total 91 69
Prevalence 1:1380 1:540
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using the MEDPED criteria and the DLCN criteria are
shown in Tables 1 and 2, respectively.
4. Discussion
Familial hypercholesterolemia is an autosomal genetic
disease, characterized by elevated lipid levels and a severe
and early onset of coronary heart disease. Affected subjects
are therefore at high cardiovascular risk and need to be
identified as early as possible in order to establish effective
preventive treatments.
Commonly, however, the recognition of FH is far below
the expected [5]. This is particularly crucial because of the
high CV risk of young or relatively young persons, who
would be at low risk on the basis of traditional charts or
algorithms.
In the current practice of general medicine, the identifi-
cation of family forms can be only opportunistic (that is, as
a result of contacts required by the patient for various
reasons), since the active screening procedures are still not
compatiblewith the available resources. Thismeans that GPs
have a great diagnostic potential [14,15]: the high number of
contacts with most of the population assisted by the GP in
a few years allows a systematic and effective approach to this
problem, simply applying what is already recommended by
the guidelines as normal good clinical practice.
The cut-off of 190 mg/dL for LDL-C would be a first
screening. The prevalence found in the population in this
study means that, on average, a GP would identify about 30individuals per 1000 patients. Then, the diagnosis should be
based on the deepening of the patient’s personal and family
pathological history and on a clinical examination aimed to
detect the presence of any signs of illness, such as xan-
thomas, xanthelasma, or non-senile arcus cornealis. Prev-
alence data published so far suggest that, on average, each
doctor might find 2e5 FH subjects per 1000 patients [5].
The clinical diagnosis should be confirmed in the genetic
analysis of candidate genes, searching for causative muta-
tions [16]. The high levels of LDL-C in FH subjects are due to
an absent or reduced removal of LDL from the bloodstream,
whichmay be due to a deficiency of synthesis or to an altered
function of the LDL receptor (LDLR), caused by mutations
in the gene encoding the LDL receptor or other molecules
involved in its metabolism [16]. Moreover, to identify
a causative mutation means being able to make a definitive
diagnosis, excluding secondary hypercholesterolemia and to
distinguish between the classical FH due to LDLRmutations
and the other genetic causes of FH. Notably, many clinically
diagnosed FH patients fail to show any mutation in the
candidate genes [17,18]. This diagnostic gap could be
explained by mutations in other unknown novel genes that
are involved in cholesterol metabolism but, most probably,
by an accumulation of common small-effect LDL-C-raising
alleles. As a result, a substantial proportion of the raised
LDL-C concentrations in patients with a clinical diagnosis of
FH with no detected causative mutation have a polygenic
rather than a monogenic cause [19]. For these individuals
(and their relatives), the absence of mutation as from genetic
analysis does not mean absence of disease: the signs and
symptoms of the disease, primarily the high LDL-C levels,
should be the target of a specific therapy.
Given the hereditary transmission of the disease, the
cascade screening of relatives should follow the identifi-
cation of an affected person (index patient) [14,20]. In fact,
it is important to underline that, in most cases, the GP has
to manage an entire family unit, so that effective commu-
nication with all family members is a key point to make
patients more conscious of their condition, in order to
encourage changes in lifestyle and improve adherence to
drug treatment.
The relatively asymptomatic nature, at least until the
development of coronary heart disease, and its epidemio-
logical frequency make FH a preferential target for the
general practitioner. Using the lipid profile as a starting
point and taking advantage of the software for the
29M. Casula et al. / Atherosclerosis Supplements 29 (2017) 25e30management of clinical data now available to general
practice, GPs can easily select a small group of patients for
further assessment to early diagnose the disease and, as
applicable, initiate or strengthen the lipid-lowering therapy
as soon as possible. The diagnosis of FH is therefore
possible within general medicine and should be integral
part of the GP’s activity, also because GPs are in the
best position to identify patients before they manifest CV
events.
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Consorzio Sanita` (Co.S.) was founded in 1997 and it is
a national group of 29 cooperatives, which have more than
2300 General Practitioners (GPs) as members, assisting
more than 2.6 million citizens across 10 Italian regions
(Lombardy, Veneto, Emilia-Romagna, Liguria, Toscana,
Lazio, Campania, Abruzzo, Calabria and Sicilia).
Co.S.’s mission is to build a framework for integrated
services for AFT/UCCP groups, within a multi-professional
(both Medical and Social services), cooperative organiza-
tion which focuses on comprehensive care-taking paths for
chronic and fragile patients.
Co.S. Centro Studi (research center) http://www.
centrostudicos.org/
Individual GPs and cooperatives take part in Centro
Studi Co.S. (Co.S. research center), whose goal is to study,
define and implement specific projects that align with
Co.S.’s mission, in the following areas:
 Epidemiological studies:
- Prevalence studies (especially for chronic
conditions)
- Identification of risk factors: cardiovascular
conditions, diabetes, cancer.
 Observational studies:
- “Natural” trends for major chronic conditions, with
assessment of the related end points
- Assessment of efficacy of pharmaceutical treat-
ments, as well as lifestyle counselling, towards
reducing intermediate outcome indicators
 Projects aimed at prevention and well-being:
Centered on correlation between obesity and diabetes,
smoking and lung cancer, fitness and cardiovascular
conditions.
 Clinical Governance:
Analysis of performance indicators, both professional
and organizational, in managing care-taking paths for
chronic and fragile patients, for an adequate reallocation of
resources.“My Search” database
Practitioners joining the Centro Studi submit at least
monthly data they produce in their daily clinical practice.This
data is sent from their electronic medical record software to
Centro Studi, without any limitation on the type of electronic
medical record software they use. The Centro Studi software
framework is based on an interoperability tool, OSM-Con-
nector, which can extract data from any electronic medical
record software and, after anonymization; it creates a stan-
dardXML record (shared acrossmultiple SWvendors) which
it sends via a VPN tunnel to Centro Studi.
The Centro Studi Database Management System is
MariaDB, which is a MySQL fork running in Linux. This is
a free software database; it is open to dialogue with the
community and focuses on a good interoperability with
other softwares, a philosophy aligned with Co.S.’s own.
As of writing (Nov 2016), 602 GPs contribute to the My
Search database, covering 871,634 citizens
“My Search” portal
The portal allows GPs to run predefined queries, which
offers them a powerful tool to perform:
 Self-Auditing, with possibility to receive coaching from
his/her co-op to reach his/her prescription appropri-
ateness goals, as agreed with Local Health Authority
 Pathology Records, to monitor prevalence of major
chronic conditions (including a geographic epidemi-
ology map)
 Clinical Governance, analysis of professional perfor-
mance indicators in managing care-taking paths to
manage chronicity
 Continuous Quality Improvement, elaboration of
specific process and outcome indicators, aimed at
continuous quality improvement
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